---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-017075"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:07:51.886538+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce

## Summary
- Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.
- Expects $1.1M severance charges; cash runway extended to second half of 2026.
- Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.
- Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets.

## SEC filing metadata
- accession: 0000950170-25-017075
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/0000950170-25-017075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-017075
- JSON: https://secwatch.observer/filing/0000950170-25-017075.json
- Plain text: https://secwatch.observer/filing/0000950170-25-017075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.